Spearheading a Novel Drug Candidate in Chronic Inflammatory Skin and Joint Diseases

Time: 11:30 am
day: Day 1 AM - Track B


  • Outlining the emerging story of IL-17A and F in inflammatory diseases
  • How to Optimize targeting an important cytokine pathway – MOA and unique molecule characteristics of the novel IL-17 drug candidate sonelokimab
  • Showcasing disease control by sonelokimab from a phase 2b trial in psoriasis
  • Broadening the spectrum – Preparing for success in HS and PsA